RGNX(REGENXBIO Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $470.35M | $112.72M | $90.24M | $83.33M | $170.44M |
| 毛利润 | $418.51M | $58.18M | $53.03M | $49.76M | — |
| 营业利润 | $159.98M | −$262.88M | −$268.13M | −$233.35M | −$161.20M |
| 净利润 | $127.84M | −$280.32M | −$263.49M | −$227.10M | −$193.88M |
| 经营现金流 | $218.88M | −$207.49M | −$218.41M | −$173.12M | −$123.96M |
| 自由现金流 | $134.70M | −$238.21M | −$228.37M | −$175.56M | −$126.38M |
| 摊薄每股收益 | $2.91 | $-6.50 | $-6.02 | $-4.59 | $-3.76 |